Evidence map›Paper›PMID 29563997›Full record

ArticleOncology letters2018

Effects of combined radiosurgery and temozolomide therapy on epidermal growth factor receptor and variant III in glioblastoma multiforme.

Yiguang Lin, Junhu Zhou, Jianglong Xu, Kai Zhao, Xiaomin Liu, Guokai Wang, Zhiyuan Zhang, Youlin Ge, Yongqing Zong, Desheng Xu and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Yiguang LinGamma Knife Centre, Department of Neurosurgery, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China.
Junhu ZhouTianjin Neurological Institute, Department of Neurosurgery, Tianjin Medical University, General Hospital and Laboratory of Neurooncology, Tianjin 300052, P.R. China.
Jianglong XuDepartment of Neurosurgery, Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China.
Kai ZhaoGamma Knife Centre, Department of Neurosurgery, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China.
Xiaomin LiuGamma Knife Centre, Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin 300350, P.R. China.
Guokai WangGamma Knife Centre, Department of Neurosurgery, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China.
Zhiyuan ZhangGamma Knife Centre, Department of Neurosurgery, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China.
Youlin GeGamma Knife Centre, Department of Neurosurgery, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China.
Yongqing ZongGamma Knife Centre, Department of Neurosurgery, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China.
Desheng XuGamma Knife Centre, Department of Neurosurgery, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China.
Yanli TanDepartment of Neurosurgery, Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China.
Chuan FangDepartment of Neurosurgery, Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China.
Chunsheng KangTianjin Neurological Institute, Department of Neurosurgery, Tianjin Medical University, General Hospital and Laboratory of Neurooncology, Tianjin 300052, P.R. China.
Tianjin Medical University · CNSecond Hospital of Tianjin Medical University · CNAffiliated Hospital of Hebei University · CNTianjin Huanhu Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is a highly malignant and notably aggressive primary tumour. Variant III of the epidermal growth factor receptor (EGFRvIII) is one of the most common types of variants in GBM, and serves an important role in tumour invasion, proliferation and treatment resistance. In the present study, statistical analyses were performed on data from 57 patients with GBM, and polymerase chain reaction detection was conducted on the tumour tissues from 32 of these patients. The results indicated that the EGFRvIII mutation was significantly associated with tumour malignancy. Human GBMU87-EGFRvIII cell lines were cultured and treated with radiosurgery and temozolomide individually, or with combined radiosurgery and temozolomide treatment.

Indexed as

epidermal growth factor receptor variant IIIinvasionproliferationradiation treatmenttemozolomidevariant

Identifiers

PMID29563997
PMCPMC5858087
OpenAlexW2789068844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.